Multiple Sclerosis Journal · 2017 · 15 citations · 3 references
Life SciencesHematologyImmunologyAutoimmunityImmunotherapyMonoclonal AntibodiesAutoimmune Hematologic DiseaseMonoclonal Antibody TherapyMultiple SclerosisPlatelet DisordersPlatelet PhysiologyTherapeutic Monoclonal AntibodiesAlemtuzumab UseAutoimmune ThrombocytopeniaBruisingImmune-mediated ThrombocytopeniaMonoclonal Antibody InfusionPlatelet Count MonitoringRelapsing-remitting Multiple Sclerosis TreatmentSecondary Autoimmune Hematologic Disorders
BACKGROUND: Alemtuzumab is a monoclonal antibody approved for relapsing-remitting multiple sclerosis (RRMS). Although Immune thrombocytopenia (ITP) has been reported as a secondary autoimmune phenomenon following alemtuzumab infusion, immediate thrombocytopenia during the infusion has not been reported. OBJECTIVE: We report transient, reversible, self-limiting acute-onset thrombocytopenia during the first course with alemtuzumab. RESULTS AND CONCLUSION: In total, 3 of 22 paitents developed mild self-limited bruising associated with a drop in platelet count from their baseline during the intial 5-day course of alemtuzumab. Upon chart review, all 22 patients who received alemtuzumab developed an immediate mostly asymptomatic drop in platelet count which returned to normal within 2 months post-infusion.
3